Elisidepsin
Also known as: Elisidepsin, IB-01212, Irvalec, PM027, PM02734
Source Elisidepsin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Elisidepsin (PM027) is a synthetic cyclic peptide derived from marine natural products, investigated as an anticancer agent for solid tumors. Administered by intravenous infusion in early‑phase clinical trials.
Mechanism of Action
Induces rapid oncosis by disrupting tumor cell membranes, leading to necrotic cell death independent of apoptosis pathways.
Routes of Administration
Goals & Uses
- Solid tumor oncologyOncologyModerate
- Treatment of non-small cell lung cancer (NSCLC)OncologyLow
- Anticancer activity in solid tumorsOncologyModerate
- Membrane-targeting cytotoxicityMechanistic/ResearchModerate
- Treatment of head and neck squamous cell carcinomaOncologyLow
Contraindications
- Severe hepatic impairmentOrganHighLiver function concerns
- Severe renal impairmentOrganModerateKidney function concerns
- Poor performance status (ECOG >2)Clinical StatusHigh
- Known hypersensitivity to the peptide or formulation excipientsAllergyHigh
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Infusion‑related reactions (e.g., flushing, dyspnea)Infusion ReactionCommon
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- MyelosuppressionHematologicUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Mucositis/stomatitisGastrointestinalUncommon
Drug Interactions
- CYP3A4 inhibitorsModerate
- Other cytotoxic chemotherapeuticsModerate
- CYP450 inhibitors or inducersLow
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveAbsolute
- LactationReproductiveAbsolute
- Elderly patients (>75 years)AgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorisation; not approved by EMA.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalUnder clinical investigation; not licensed by MHRA.
Phase II clinical trials completed for colorectal cancer and melanoma; not approved in any major jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Elisidepsin?
Elisidepsin (PM027) is a synthetic cyclic peptide derived from marine natural products, investigated as an anticancer agent for solid tumors. Administered by intravenous infusion in early‑phase clinical trials.
What is Elisidepsin used for?
Elisidepsin is educationally associated with: Solid tumor oncology, Treatment of non-small cell lung cancer (NSCLC), Anticancer activity in solid tumors, Membrane-targeting cytotoxicity, Treatment of head and neck squamous cell carcinoma. Educational only — not medical advice.
How is Elisidepsin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Elisidepsin?
Reported adverse effects include: Peripheral neuropathy, Hypotension, Infusion‑related reactions (e.g., flushing, dyspnea), Nausea and vomiting, Nausea, Fatigue, Myelosuppression, Elevated liver enzymes, Mucositis/stomatitis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Elisidepsin?
Recorded contraindications: Severe hepatic impairment, Severe renal impairment, Poor performance status (ECOG >2), Known hypersensitivity to the peptide or formulation excipients. Consult a qualified clinician before use.